Mode
Text Size
Log in / Sign up

Individual patient data meta-analysis links blood neurofilament light chain levels to ischemic stroke outcomesHigh blood NfL levels predict worse outcomes after ischemic stroke

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher blood NfL levels associate with worse 3-month outcomes in ischemic stroke patients.

This individual patient data meta-analysis examined blood neurofilament light chain (NfL) levels in a cohort of 2872 participants. The population included 1985 patients with ischemic stroke, 88 with transient ischemic attack, and 799 healthy controls. The primary outcomes assessed at 3 months included the modified Rankin Scale and survival. The study also evaluated secondary outcomes such as symptomatic intracranial hemorrhage and infarct lesion volume.

The results indicated high discriminative ability for distinguishing ischemic stroke from controls, with an AUC ranging from 0.79 to 0.97. Discriminative ability for ischemic stroke versus transient ischemic attack was fair, with an AUC between 0.64 and 0.80. NfL Z-scores progressively increased from day 1 to day 6 or 7, with a median of 2.0 at day 1 and 3.5 at day 6 or 7.

Higher NfL Z-scores at day 1 were associated with a greater risk of symptomatic intracranial hemorrhage, with an adjusted odds ratio of 1.33 and a p-value of 0.014. Larger infarct lesion volume was associated with higher NfL Z-scores from day 2 onwards, reaching a Spearman's rho of 0.795 at day 6 or 7. Higher NfL Z-scores independently predicted mRS scores greater than 2 at 3 months (adjusted odds ratio 1.31, p<0.001) and mortality at 3 months (adjusted odds ratio 1.67, p<0.001).

Safety data, including adverse events and tolerability, were not reported. The authors did not report funding or conflicts of interest. The study does not establish a causal relationship between NfL levels and outcomes. Clinical application remains uncertain given the observational nature of the data and lack of reported practice relevance.

This individual patient data meta-analysis examined blood levels of neurofilament light chain, known as NfL, in adults within 30 days after an ischemic stroke or transient ischemic attack. The study included 1,985 stroke patients, 88 TIA patients, and 799 healthy controls to compare biomarker levels against outcomes measured at three months.

The researchers found that NfL levels were significantly higher in stroke patients compared to healthy controls. Within the first week, these levels increased progressively in patients who suffered a stroke. Higher levels were linked to larger areas of brain damage and a greater risk of bleeding in the brain.

At the three-month follow-up, patients with higher NfL levels faced a greater risk of disability, defined as a modified Rankin Scale score above 2. Those with elevated markers also had a higher risk of death. The study suggests that measuring these blood levels early could help identify patients at risk for poor recovery.

No safety concerns were reported because the blood test itself carries no known risks. However, this is a biomarker study, not a trial of a new treatment. Readers should understand that high NfL levels are a sign of existing brain injury rather than a cause of it.

What this means for you:
Higher early blood NfL levels predict disability and death after stroke but do not cause these outcomes.

Study Details

Study typeMeta analysis
Sample sizen = 2,872
EvidenceLevel 1
Follow-up3.0 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: We aimed to conduct an individual patient data meta-analysis on blood neurofilament light chain (NfL) in ischemic stroke (IS) to enhance its clinical applicability. METHODS: We performed a systematic literature search of studies on blood NfL measured in adult patients within 30 days after IS onset and derived age- and BMI-adjusted Z-scores based on a previously published reference population of healthy controls. We collected clinical, radiological and biochemical parameters of IS patients and tested associations of NfL at defined timepoints after IS onset (D1: < 24 h; D2: 24-48 h; D3: 48-72 h; D4-5: 72-120 h; D6-7: 120-168 h; D8-30: > 168 h) with baseline characteristics and 3-month follow-up outcomes (modified Rankin Scale, mRS; survival). RESULTS: We included 4081 blood NfL values from 2872 participants (IS n = 1985, transient ischemic attack n = 88, healthy controls n = 799) of 18 published studies and 3 unpublished cohorts. In patients with IS, NfL Z-score progressively increased from D1 [median: 2.0 (IQR: 0.9-2.9)] to D6-7 [median: 3.5 (IQR: 3.0-3.8)], with discriminative ability being high for IS vs. controls (AUC: 0.79-0.97) and fair for IS vs. TIA (AUC: 0.64-0.80). Higher NfL Z-score at D1 was associated with greater risk of symptomatic intracranial hemorrhage (aOR = 1.33, p = 0.014) and, from D2 onwards, with larger infarct lesion volume (highest Spearman's rho: 0.795 at D6-7). NfL independently predicted a mRS > 2 (aOR = 1.31, p < 0.001) and mortality (aOR = 1.67, p < 0.001) at 3 months. CONCLUSIONS: Blood NfL level was progressively elevated after IS, could discriminate IS from healthy controls with high accuracy and had prognostic value for intra-hospital complications and 3-month clinical outcomes in IS.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.